Literature DB >> 11006661

Thrombolytic therapy in acute myocardial infarction: Third Irish Working Party Consensus. Irish Thrombolysis Concenus Group.

A Brown1, J Horgan, M Conway, W Fennell, H McCann, B Meaney, M O'Reilly, P Sullivan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11006661     DOI： 10.1007/bf03166907

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN： 0021-1265            Impact factor:   1.568


× No keyword cloud information.
  18 in total

Review 1.  Clinical risks of thrombolytic therapy.

Authors:  R M Califf; D F Fortin; A N Tenaglia; D C Sane
Journal:  Am J Cardiol       Date:  1992-01-03       Impact factor: 2.778

Review 2.  Effects of beta blockade on sudden cardiac death during acute myocardial infarction and the postinfarction period.

Authors:  A Hjalmarson
Journal:  Am J Cardiol       Date:  1997-11-13       Impact factor: 2.778

3.  Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators.

Authors:  E M Antman; R P Giugliano; C M Gibson; C H McCabe; P Coussement; N S Kleiman; A Vahanian; A A Adgey; I Menown; H J Rupprecht; R Van der Wieken; J Ducas; J Scherer; K Anderson; F Van de Werf; E Braunwald
Journal:  Circulation       Date:  1999-06-01       Impact factor: 29.690

Review 4.  Thrombolytic therapy in acute myocardial infarction. Irish Working Party Consensus.

Authors:  J Macken
Journal:  Ir J Med Sci       Date:  1993-04       Impact factor: 1.568

5.  Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial.

Authors:  F Van De Werf; J Adgey; D Ardissino; P W Armstrong; P Aylward; G Barbash; A Betriu; A S Binbrek; R Califf; R Diaz; R Fanebust; K Fox; C Granger; J Heikkilä; S Husted; P Jansky; A Langer; E Lupi; A Maseri; J Meyer; J Mlczoch; D Mocceti; D Myburgh; A Oto; E Paolasso; K Pehrsson; R Seabra-Gomes; L Soares-Piegas; D Sùgrue; M Tendera; E Topol; P Toutouzas; A Vahanian; F Verheugt; L Wallentin; H White
Journal:  Lancet       Date:  1999-08-28       Impact factor: 79.321

6.  Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI).

Authors: 
Journal:  Lancet       Date:  1986-02-22       Impact factor: 79.321

7.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.

Authors:  M A Pfeffer; E Braunwald; L A Moyé; L Basta; E J Brown; T E Cuddy; B R Davis; E M Geltman; S Goldman; G C Flaker
Journal:  N Engl J Med       Date:  1992-09-03       Impact factor: 91.245

8.  Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction.

Authors:  H D White; R M Norris; M A Brown; M Takayama; A Maslowski; N M Bass; J A Ormiston; T Whitlock
Journal:  N Engl J Med       Date:  1987-10-01       Impact factor: 91.245

9.  Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. The RAPID II Investigators.

Authors:  C Bode; R W Smalling; G Berg; C Burnett; G Lorch; J M Kalbfleisch; R Chernoff; L G Christie; R L Feldman; A A Seals; W D Weaver
Journal:  Circulation       Date:  1996-09-01       Impact factor: 29.690

10.  GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico.

Authors: 
Journal:  Lancet       Date:  1990-07-14       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.